Tim McCarty, a research analyst at Janus Henderson, characterizes the role of AI in healthcare as "under the radar and omnipresent." He argues that while most investors are only familiar with AI's application in drug discovery, AI is permeating the entire healthcare value chain, providing an additional growth driver for the healthcare sector, which also possesses defensive characteristics. In this interview published on November 17, 2026, he elaborates on the three-stage value path of AI in surgical robots.
The first stage, which has already been realized, is current: AI acts as a "report card" for surgeons. McCarty gives the example of a gallbladder surgeon who may take 20 minutes longer than best-in-class standards and use two extra instruments. AI can decompose the surgery into specific steps, pointing out, "You are deficient in step six," and matching training modules on practice robots. He uses the analogy of college basketball game film analysis—watching game footage, identifying deficiencies, and doing targeted drills.
The second stage is what McCarty calls the "not-too-distant future": AI eliminates medical errors and democratizes surgery. His core argument is information asymmetry—the healthcare system is rife with it, with bottom-quartile doctors responsible for a disproportionate amount of medical errors, which cost the system tens of billions of dollars annually. However, patients cannot judge a doctor's skill level before surgery, as "no one walks in saying I'm a bottom-quartile doctor." McCarty believes this asymmetry will be broken when AI can objectively evaluate every surgeon's performance.
The third stage is a long-term vision, which McCarty refers to as the "Waymo of healthcare." He points out that capacity is one of the major problems facing the current healthcare system: one surgeon per one patient. He envisions a world where, as robots autonomously complete more surgical steps, a single surgeon can "drive" multiple surgeries simultaneously, monitoring several parallel operations like a pilot, thereby alleviating supply-demand mismatches.
Sarah de Lagarde, Janus Henderson's Brighter Future Strategist, provides firsthand calibration for this narrative. She wears a bionic arm but admits its practical advantages in daily life are limited—"My biological left hand is much stronger than this arm." She notes that engineers tend to solve problems that are not truly needed in patients' daily lives, and distinguishing between "over-marketing" and "genuine benefits to patients" is precisely the job of portfolio managers. The only function she considers irreplaceable for the bionic arm is the ability to modulate grip strength at will via a smartphone app.
McCarty also mentioned AI's application in cardiovascular diagnostics. He focuses on severe aortic stenosis—a valvular disease with a 25% mortality rate if untreated—and notes that approximately 500 million people worldwide suffer from cardiovascular disease. Currently, minimally invasive replacement surgery is available at 850 centers in the United States. The opportunity for AI lies in improving diagnosis and treatment rates from primary care physicians to cardiologists and across various levels of the healthcare system.